<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04705350</url>
  </required_header>
  <id_info>
    <org_study_id>UP0105</org_study_id>
    <secondary_id>2020-004411-26</secondary_id>
    <nct_id>NCT04705350</nct_id>
  </id_info>
  <brief_title>A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants</brief_title>
  <official_title>A Randomized, Participant-Blind, Investigator-Blind, Placebo-Controlled Study Evaluating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma SRL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK)&#xD;
      of zampilimab in healthy study participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 11, 2021</start_date>
  <completion_date type="Actual">July 27, 2021</completion_date>
  <primary_completion_date type="Actual">July 27, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This is a participant- and Investigator-blind study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidents of treatment-emergent adverse events (TEAEs) through the Safety Follow-up (SFU) Visit</measure>
    <time_frame>From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)</time_frame>
    <description>A treatment-emergent adverse event (TEAE) is defined as any event not present prior to the administration of investigational medicinal product (IMP) or any unresolved event already present before administration of IMP that worsens in intensity following exposure to the treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum intensity of treatment-emergent adverse events (TEAEs) through the Safety Follow-up (SFU) Visit</measure>
    <time_frame>From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)</time_frame>
    <description>Maximum intensity across all incidents of each TEAE for each study participant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum zampilimab serum concentration (Cmax)</measure>
    <time_frame>From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)</time_frame>
    <description>Cmax: Maximum observed zampilimab serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum zampilimab serum concentration (tmax)</measure>
    <time_frame>From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)</time_frame>
    <description>tmax: Time to maximum observed zampilimab serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the zampilimab serum concentration-time curve from time zero to last quantifiable concentration (AUC0-t)</measure>
    <time_frame>From Day 1 (Start of Treatment Period) at predefined time points to the last quantifiable concentration (up to 120 days)</time_frame>
    <description>AUC0-t: Area under the zampilimab serum concentration-time curve from time zero (Day 1) to the last quantifiable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the zampilimab serum concentration-time curve from time zero to infinity (AUC)</measure>
    <time_frame>Day 1 (Start of Treatment Period) at predefined time points (up to 120 days)</time_frame>
    <description>AUC: Area under the zampilimab serum concentration-time curve from time 0 (Day 1) to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of zampilimab in serum</measure>
    <time_frame>From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)</time_frame>
    <description>CL: volume of serum that is cleared from zampilimab per unit of time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during terminal phase (Vz) of zampilimab</measure>
    <time_frame>From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)</time_frame>
    <description>Vz: apparent volume of distribution during terminal phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life (t1/2) of zampilimab</measure>
    <time_frame>From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)</time_frame>
    <description>t1/2: terminal zampilimab serum half-life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy Study Participants</condition>
  <arm_group>
    <arm_group_label>Zampilimab Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive predefined single doses of zampilimab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to this arm will receive matching Placebo to maintain the blinding.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zampilimab</intervention_name>
    <description>Participants will receive a single intravenous dose of zampilimab at a pre-specified time point.</description>
    <arm_group_label>Zampilimab Cohorts</arm_group_label>
    <other_name>UCB7858</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive matching placebo at a pre-specified time point to maintain the blinding.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>PBO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be 18 to 55 years of age inclusive, at the time of signing the&#xD;
             Informed Consent Form (ICF)&#xD;
&#xD;
          -  Study participant must be considered reliable and capable of adhering to the protocol,&#xD;
             according to the judgment of the Investigator, and is able to communicate&#xD;
             satisfactorily with the Investigator and comply with all clinical study requirements&#xD;
&#xD;
          -  Study participant has adequate peripheral venous access&#xD;
&#xD;
          -  Study participant has clinical laboratory test results within the reference ranges of&#xD;
             the testing laboratory. Study participants with test results that are outside the&#xD;
             specified ranges and that are deemed as clinically nonsignificant will be allowed at&#xD;
             the discretion of the Investigator&#xD;
&#xD;
          -  Study participant is of normal weight as determined by a body mass index between 18&#xD;
             and 32 kg/m^2, inclusive, with a body weight of at least 50 kg (male) or 45 kg&#xD;
             (female) and no greater than 100 kg&#xD;
&#xD;
          -  Study participants may be male or female&#xD;
&#xD;
          -  Male participants must agree to use contraception during treatment period and for 5&#xD;
             months; female participants of childbearing potential must be not pregnant or&#xD;
             breastfeeding and agree to use contraception during the treatment period and for 5&#xD;
             months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Study participant has any medical (acute or chronic) or psychiatric condition that, in&#xD;
             the opinion of the Investigator, could jeopardize or would compromise the study&#xD;
             participant's ability to participate in this study&#xD;
&#xD;
          -  History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal,&#xD;
             endocrinological, hematological, or neurological disorders capable of significantly&#xD;
             altering the absorption, metabolism, or elimination of drugs; constituting a risk when&#xD;
             taking the IMP; or interfering with the interpretation of data&#xD;
&#xD;
          -  Study participant has a known hypersensitivity to any components of the&#xD;
             investigational medicinal product (IMP) as stated in this protocol or participant has&#xD;
             a history of moderate to severe allergic reaction to medication(s), including&#xD;
             biologics&#xD;
&#xD;
          -  Study participant has any clinically relevant abnormal findings in physical&#xD;
             examination, laboratory tests, vital signs, or electrocardiogram (ECG), which, in the&#xD;
             opinion of the Investigator, may place the participant at risk because of&#xD;
             participation in the study&#xD;
&#xD;
          -  Study participant has had major surgery (including joint surgery) within 6 months&#xD;
             prior to the Screening Period, or has planned surgery within 6 months after IMP&#xD;
&#xD;
          -  Study participant has current diagnosis or history of wound healing complications&#xD;
&#xD;
          -  Study participant has a history of alcohol and/or drug abuse up to 6 months before the&#xD;
             Screening Period&#xD;
&#xD;
          -  Study participant has active neoplastic disease or history of neoplastic disease&#xD;
             within 5 years of the Screening Period&#xD;
&#xD;
          -  Study participant has an active infection during the Screening Period&#xD;
&#xD;
          -  Study participant has clinical signs and symptoms consistent with coronavirus disease&#xD;
             (COVID-19) or had a positive severe acute respiratory syndrome coronavirus 2&#xD;
             (SARS-CoV-2) test result within the last 4 weeks prior to the Screening Period or on&#xD;
             admission&#xD;
&#xD;
          -  Study participant has had a severe course of COVID-19 that required hospitalization&#xD;
&#xD;
          -  Study participant has received any prescription or nonprescription medicines,&#xD;
             including over the counter (OTC) remedies or herbal and dietary supplements, within 14&#xD;
             days or 5 half-lives of the respective drug, whichever is longer, other than the&#xD;
             occasional use of analgesics, such as paracetamol (acetaminophen) or ibuprofen, oral&#xD;
             contraceptives, or inhaled corticosteroids for seasonal rhinitis&#xD;
&#xD;
          -  Study participant has received treatment with biologic agents (such as monoclonal&#xD;
             antibodies (mAbs) including marketed drugs) within 3 months or 5 half-lives (whichever&#xD;
             is longer) prior to dosing&#xD;
&#xD;
          -  Study participant has received a vaccination within 8 weeks prior to Day 1; or intends&#xD;
             to have a vaccination during the course of the study&#xD;
&#xD;
          -  Study participant has participated in another study of a IMP (and/or an&#xD;
             investigational device) within the previous 3 months or 5 half-lives prior to the&#xD;
             Screening Period, whichever is longer, or is currently participating in another study&#xD;
             of a IMP (and/or an investigational device)&#xD;
&#xD;
          -  Study participant has positive serology test for hepatitis B surface antigen,&#xD;
             hepatitis B core antibodies (both immunoglobulin G (IgG) and IgM), hepatitis C virus&#xD;
             antibodies, or antibodies to human immunodeficiency virus type 1 and/or type 2 during&#xD;
             the Screening Period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Principal Investigator</role>
    <affiliation>001 844 599 2273 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Up0105 001</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>January 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy study participants</keyword>
  <keyword>UCB7858</keyword>
  <keyword>zampilimab</keyword>
  <keyword>Phase 1</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Due to the small sample size in this trial, IPD cannot be adequately anonymized i.e., there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

